Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials

医学 肾脏疾病 肾功能 内科学 随机对照试验 肌酐 阶段(地层学) 重症监护医学 生物 古生物学
作者
Muhammad Shahzeb Khan,George L. Bakris,Izza Shahid,Matthew R. Weir,Javed Butler
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:7 (5): 549-549 被引量:18
标识
DOI:10.1001/jamacardio.2021.5151
摘要

Importance

Cardiovascular trials have traditionally been underpowered to assess advanced chronic kidney disease (CKD) outcomes, and when included as a secondary end point, trials have used progression of CKD as incidence of some variation of a composite of end-stage kidney disease (ESKD) outcomes. Such outcomes are infrequent or occur late in cardiovascular outcome trials, which highlights the need for alternate markers for assessing the impact of interventions on kidney function at an earlier stage of the disease and, from the prevention perspective, more relevant stage of the disease.

Observations

Estimated glomerular filtration rate (eGFR) slope has demonstrated strong association with subsequent progression to ESKD. With adequate sample size, treatment effects in the range of 0.5 to 1.00 mL/min/1.73 m2/y had 96% probability of predicting CKD progression, defined as doubling of serum creatinine, eGFR less than 15 mL/min/1.73 m2, or ESKD. eGFR slope can be used in patients with higher baseline values and may provide CKD progression insights when few hard kidney events are observed, especially in trials with limited follow-up. However, among trials that have determined eGFR slope, significant variations exist regarding inclusion of baseline values, calculation of eGFR values, and the follow-up period, which make it difficult to compare and gauge the incremental benefit of the interventions. There are multiple challenges in computing eGFR slope in cardiovascular trials, such as accounting for initial eGFR dip, nonlinearity, and heteroscedasticity.

Conclusions and Relevance

eGFR slope may serve as a valuable marker to determine progression of CKD in cardiovascular trials. Further work is required to standardize data collection, follow-up duration, time points for kidney function assessment, and analytic methods to compute eGFR slope in cardiovascular trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci应助qwe1108采纳,获得10
1秒前
明天过后完成签到,获得积分10
3秒前
jin完成签到,获得积分10
4秒前
yhy完成签到 ,获得积分10
5秒前
黑色卡布奇诺完成签到,获得积分20
5秒前
tanglu发布了新的文献求助10
5秒前
可爱的函函应助梁大海采纳,获得10
5秒前
成就绮琴完成签到 ,获得积分10
6秒前
xicifish完成签到,获得积分10
6秒前
目光之澄完成签到,获得积分10
7秒前
wanci应助研友_ndDPBn采纳,获得10
7秒前
耍酷的白梦完成签到,获得积分10
8秒前
miracle完成签到 ,获得积分10
9秒前
coding完成签到,获得积分10
10秒前
11秒前
犹豫水蓝完成签到,获得积分10
12秒前
yin完成签到,获得积分10
12秒前
JUGG完成签到,获得积分10
12秒前
CipherSage应助阿湫采纳,获得10
13秒前
FIN应助手机采纳,获得20
13秒前
星辰大海应助东黎采纳,获得10
13秒前
量子星尘发布了新的文献求助10
13秒前
wujingshuai完成签到,获得积分10
14秒前
少年完成签到,获得积分10
14秒前
星辰大海应助ficus_min采纳,获得10
15秒前
小柒柒完成签到,获得积分10
16秒前
sdfwsdfsd完成签到,获得积分10
17秒前
亮仔完成签到,获得积分10
18秒前
土豆丝发布了新的文献求助10
18秒前
ylw完成签到,获得积分20
19秒前
西门明雪完成签到,获得积分10
19秒前
19秒前
烟花应助万松辉采纳,获得10
20秒前
爆米花应助不站在雾里采纳,获得10
20秒前
yy完成签到,获得积分20
21秒前
高贵宛海完成签到,获得积分10
21秒前
854fycchjh完成签到,获得积分10
22秒前
23秒前
研友_ndDPBn发布了新的文献求助10
23秒前
番茄发布了新的文献求助30
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048